Dominick Colangelo
Directeur Général chez VERICEL CORPORATION
Fortune : 10 M $ au 30/06/2024
Profil
Dominick C.
Colangelo currently works at Vericel Corp., as President, Chief Executive Officer & Director from 2013 and Trevi Therapeutics, Inc., as Independent Director from 2020.
Mr. Colangelo also formerly worked at Promedior, Inc., as President, Chief Executive Officer & Director from 2011 to 2012, Eli Lilly & Co., as Director-Strategy & Business Development, LV Management Group, LLC, as Managing Director, and Oscient Pharmaceuticals Corp., as Executive VP-Corporate Development & Operations from 2005 to 2008.
Mr. Colangelo received his undergraduate degree from State University of New York at Buffalo and graduate degree from Duke University School of Law.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VERICEL CORPORATION
0,45% | 13/06/2024 | 220 752 ( 0,45% ) | 10 M $ | 30/06/2024 |
TREVI THERAPEUTICS, INC.
-.--% | 13/06/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
Postes actifs de Dominick Colangelo
| Sociétés | Poste | Début |
|---|---|---|
| VERICEL CORPORATION | Directeur Général | 01/03/2013 |
| TREVI THERAPEUTICS, INC. | Directeur/Membre du Conseil | 29/06/2020 |
Anciens postes connus de Dominick Colangelo
| Sociétés | Poste | Fin |
|---|---|---|
Promedior, Inc.
 Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | Directeur Général | 15/05/2012 |
Oscient Pharmaceuticals Corp.
 Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Directeur des opérations | 11/12/2008 |
LV Management Group, LLC
 LV Management Group, LLC Investment ManagersFinance Lilly Ventures Management Group LLC (Lilly ventures) is a venture capital firm, a subsidiary of Eli Lilly & Co. founded in 2001 by S.Edward Torres and Ron Laufer. The firm is headquartered in Indianapolis,Indiana. | Directeur en chef des Investissements | 07/12/2005 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Formation de Dominick Colangelo
| State University of New York at Buffalo | Undergraduate Degree |
| Duke University School of Law | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| VERICEL CORPORATION | Health Technology |
| TREVI THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
LV Management Group, LLC
LV Management Group, LLC Investment ManagersFinance Lilly Ventures Management Group LLC (Lilly ventures) is a venture capital firm, a subsidiary of Eli Lilly & Co. founded in 2001 by S.Edward Torres and Ron Laufer. The firm is headquartered in Indianapolis,Indiana. | Finance |
Oscient Pharmaceuticals Corp.
Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Commercial Services |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | Health Technology |
